AMIBM welcomes Chinese PhD researcher
The Chinese Scholarship Council has announced that they have granted a scholarship to a PhD-student to come to the Maastricht University for developing a novel wound dressing that is completely derived from the stinging nettle Urtica dioica.
This plant will provide fibers for the dressings as well as bioactive compounds to prevent infection, regulate inflammation and stimulate wound healing. These novel wound dressings will be important for treatment of chronic wounds with human patients.
The supervisors of this PhD-research project will be dr. Menno Knetsch, associate professor in Biobased Materials & Biology, and prof. dr. Stefan Jockenhövel, professor in Tissue Engineering & Textile Implants and scientific director of the Aachen-Maastricht Institute of Biobased Materials.
About the Aachen-Maastricht Institute for Biobased Materials (AMIBM)
AMIBM is a cross-border cooperation between Maastricht University, RWTH Aachen and Fraunhofer IME. AMIBM’s vision is to provide the missing link between fundamental and applied research and the market in the field of biobased materials. It aims to do this by changing the relationship between the production of biobased materials and the value chain.
The goal is to achieve this by developing an integrated, interdisciplinary research program. The program focusses on new strategies to produce advanced biobased materials in a sustainable and economical way. It also emphasizes the development of these novel materials into innovative products with high added value for technical and medical applications.
Relevant links
- https://www.maastrichtuniversity.nl/amibm
- https://www.maastrichtuniversity.nl/biobasedmaterials
Also read
-
€250,000 for the project ‘Dynamic3D: Real-Time Simulation and Analysis for 3D Scholarly Editions’.
-
For the second time in a row, a UM team has managed to win a gold medal in the prestigious iGEM (International Genetic Engineered Machine) competition in synthetic biology.
-
Researchers from CARIM and MUMC+ discovered a potential new treatment option for patients with diastolic heart failure and atrial fibrillation.